China Pharma Holdings, Inc. States It Knows of No Events That Could Have Caused Unusual Market Activity

Rhea-AI Summary

China Pharma Holdings (NYSE American: CPHI) reported that NYSE American contacted the company following unusual trading activity in its common stock on July 10, 13, and 15, 2026. China Pharma stated it is not aware of any material nonpublic information or undisclosed business developments that would explain the recent market activity.

Market reaction after market activity statement: CPHI +78.92% in the Jul 15 session

+78.92% 43.9x vol

230 alerts

+78.92% Session close to close

+198.8% Peak in 7 hr 12 min

$44.57M Market Cap

43.9x Rel. Volume

In the Jul 15 session, CPHI gained 78.92%, reflecting a significant positive market reaction. Argus tracked a peak move of +198.8% during that session. Our momentum scanner triggered 230 alerts that day, indicating exceptionally high trading interest and price volatility. Trading volume was exceptionally heavy at 43.9x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +78.9% in the session following this news. A strong upside move following this mark...

Analysis

The stock surged +78.9% in the session following this news. A strong upside move following this market activity statement would echo the prior similar disclosure that preceded a 24.45% gain. Historical reactions show the name can swing sharply on clarifications, but with low reported short positioning, a squeeze-driven spike could prove fragile.

Key Figures

Unusual trading dates: July 10, 13, and 15, 2026

1 metrics

Unusual trading dates July 10, 13, and 15, 2026 NYSE American inquiry into recent market activity

Historical Context

1 past event · Latest: May 14 (Neutral)

Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
May 14	Market activity comment	Neutral	+24.4%	Company said no undisclosed events explained prior unusual trading in its shares.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The only comparable prior “no unusual events” statement saw a sizable positive price move, indicating the stock has reacted sharply to such disclosures before.

Key Terms

unusual market activity, material nonpublic information

2 terms

unusual market activity financial

"in view of the unusual market activity in the common stock"

A pattern of trading in a stock that departs sharply from its recent norms — for example sudden large swings in price or volume — suggesting something unusual is driving demand or supply. Like a sudden crowd forming outside a shop, it can signal new information, investor excitement, or potential manipulation, so investors pay attention as a prompt to investigate, reassess risk, or consider adjusting positions.

material nonpublic information regulatory

"it is not aware of any material nonpublic information or business developments"

Nonpublic information is specific, important news about a company or its securities that has not been shared with the general public and that a reasonable investor would consider likely to affect the company’s stock price. It matters to investors because using or sharing that information to buy or sell securities can give an unfair advantage and is often illegal; think of it like having the exam answers before a test, which undermines a fair playing field for everyone.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HAIKOU, China, July 15, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced that, in view of the unusual market activity in the common stock of China Pharma on July 10, 13, and 15, 2026, the NYSE American has contacted the Company in accordance with its usual practice. The Company stated that, while its policy generally is not to comment on unusual market activity, it is not aware of any material nonpublic information or business developments that have not been publicly disclosed that would account for the recent trading activity.

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high-margin business model is driven by market demand and supported by eight scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com. The Company routinely posts important information on its website.

Safe Harbor Statement 

Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as the achievability of financial guidance, success of new product development, unanticipated changes in product demand, increased competition, downturns in the Chinese economy, uncompetitive levels of research and development, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations except as required by applicable law or regulation.

Contact:

China Pharma Holdings, Inc. 
Phone: +86-898-6681-1730 (China)
Email: hps@chinapharmaholdings.com

View original content:https://www.prnewswire.com/news-releases/china-pharma-holdings-inc-states-it-knows-of-no-events-that-could-have-caused-unusual-market-activity-302826618.html

SOURCE China Pharma Holdings, Inc.

FAQ

Why did China Pharma Holdings (CPHI) issue a statement on July 15, 2026?

China Pharma issued the statement after NYSE American contacted the company regarding unusual trading activity in CPHI shares. According to China Pharma, it responded to confirm its position on any undisclosed material information or business developments.

What unusual market activity affected China Pharma Holdings (CPHI) stock in July 2026?

China Pharma reported that NYSE American contacted the company about unusual trading activity in its common stock on July 10, 13, and 15, 2026. According to China Pharma, the inquiry followed the exchange’s usual practice in such circumstances.

Does China Pharma Holdings (CPHI) know of any material nonpublic information behind the stock move?

According to China Pharma, the company is not aware of any material nonpublic information or undisclosed business developments that would account for the recent unusual trading activity in its CPHI common stock on NYSE American.

How did China Pharma Holdings (CPHI) respond to NYSE American’s inquiry about trading activity?

China Pharma stated that, although it generally does not comment on unusual market activity, it informed NYSE American that it knows of no material nonpublic information or undisclosed business developments explaining the recent trading in CPHI shares.

What is China Pharma Holdings’ policy on commenting about unusual market activity in CPHI stock?

According to China Pharma, the company’s general policy is not to comment on unusual market activity. In this case, it made an exception to clarify that it is unaware of undisclosed material information behind the recent trading patterns.